Engineered Alginate Microcapsules for Molecular Therapy Through Biologic Secreting Cells

Area of Science:

• Biomaterials Science
• Immunology
• Drug Delivery Systems

Background:

• Continuous delivery of monoclonal antibodies (mAbs) shows promise for managing chronic and autoimmune diseases.
• Current in vivo mAb therapy often requires complex in vitro manipulations.
• Hybridoma cells (HY) secreting mAbs offer a potential therapeutic source but require protection from the host immune system.

Purpose of the Study:

• To engineer alginate (AG)-based microcapsules with membranes permeable to large molecules, specifically mAbs.
• To enable in vivo delivery of therapeutic mAbs produced by encapsulated hybridoma cells.
• To assess the biocompatibility, immunoprotection, and drug release kinetics of the modified microcapsules.

Main Methods:

• Fabrication of novel AG-based microcapsules using modified coating procedures and molar ratios.
• Assessment of membrane permeability to large molecules, including IgM.
• Morphologic and ultrastructural analysis of microcapsules before and after intraperitoneal transplant.
• In vitro and in vivo evaluation of IgM outflow kinetics and hybridoma cell viability.

Main Results:

• Successfully created AG-based microcapsules with membranes permeable to large molecules like IgM.
• Demonstrated immunoprotection of encapsulated hybridoma cells, evidenced by a lack of inflammatory response post-transplant.
• Confirmed regulated, continuous release of G3c mAb in vitro and in vivo.
• Maintained hybridoma cell viability for extended periods after transplantation.

Conclusions:

• The novel AG-based microcapsules facilitate the controlled release of large therapeutic molecules while shielding encapsulated cells from immune rejection.
• This technology offers a potential platform for implanting cells that produce active biologics, bypassing costly purification processes.
• The engineered microcapsules hold promise for advanced in vivo antibody-based therapies for chronic diseases.